ECSP077980A - Inhibidores de la actividad akt - Google Patents

Inhibidores de la actividad akt

Info

Publication number
ECSP077980A
ECSP077980A EC2007007980A ECSP077980A ECSP077980A EC SP077980 A ECSP077980 A EC SP077980A EC 2007007980 A EC2007007980 A EC 2007007980A EC SP077980 A ECSP077980 A EC SP077980A EC SP077980 A ECSP077980 A EC SP077980A
Authority
EC
Ecuador
Prior art keywords
akt activity
activity inhibitors
akt
stipulates
compounds
Prior art date
Application number
EC2007007980A
Other languages
English (en)
Inventor
Donna J Armstrong
Essa H Hu
Michael J Kelly Iii
Mark E Layton
Yiwei Lii
Jun Liang
Kevin J Rodzinak
Michael A Rossi
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ECSP077980A publication Critical patent/ECSP077980A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención actual estipula compuestos de naftiridina sustituidos que inhiben actividad Akt. En particular, los compuestos descritos inhiben selectivamente una o dos de las isoformas de Akt. La invención también estipula composiciones que comprenden tales compuestos inhibidores y procedimientos para inhibir actividad Akt administrando el compuesto a un paciente en necesidad de tratamiento de cáncer.
EC2007007980A 2005-06-10 2007-12-03 Inhibidores de la actividad akt ECSP077980A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68972605P 2005-06-10 2005-06-10
US73418805P 2005-11-07 2005-11-07

Publications (1)

Publication Number Publication Date
ECSP077980A true ECSP077980A (es) 2008-01-23

Family

ID=37532789

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007980A ECSP077980A (es) 2005-06-10 2007-12-03 Inhibidores de la actividad akt

Country Status (22)

Country Link
US (1) US8008317B2 (es)
EP (1) EP1898903B8 (es)
JP (1) JP5055494B2 (es)
KR (1) KR100959771B1 (es)
AU (1) AU2006258124B8 (es)
BR (1) BRPI0611717A2 (es)
CA (1) CA2610888C (es)
CR (1) CR9580A (es)
DK (1) DK1898903T3 (es)
EC (1) ECSP077980A (es)
ES (1) ES2409168T3 (es)
HR (1) HRP20130429T1 (es)
IL (1) IL187690A (es)
MX (1) MX2007015578A (es)
NI (1) NI200700320A (es)
NO (1) NO20080150L (es)
NZ (1) NZ563423A (es)
PL (1) PL1898903T3 (es)
PT (1) PT1898903E (es)
RU (1) RU2421454C2 (es)
TW (1) TW200800166A (es)
WO (1) WO2006135627A2 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544677B2 (en) 2004-08-23 2009-06-09 Merck & Co., Inc. Inhibitors of Akt activity
WO2006135627A2 (en) 2005-06-10 2006-12-21 Merck & Co., Inc. Inhibitors of akt activity
TW200806670A (en) * 2006-04-25 2008-02-01 Merck & Co Inc Inhibitors of checkpoint kinases
EP2120951A4 (en) * 2006-12-06 2012-02-15 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
EP2139333A4 (en) * 2007-03-28 2010-11-10 Merck Sharp & Dohme SUBSTITUTED PYRID- [3,2-E] - [1,2,4] -TRIAZOL- [4,3-C] -PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CA2692502C (en) 2007-07-05 2016-03-01 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
CA2694058C (en) 2007-08-14 2016-06-07 Bayer Schering Pharma Aktiengesellschaft Fused bicyclic pyrimidines
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
JP2011522047A (ja) * 2008-06-03 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
US8207169B2 (en) * 2008-06-03 2012-06-26 Msd K.K. Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D
CA2730844A1 (en) 2008-07-17 2010-01-21 Thomas Bretschneider Heterocyclic compounds used as pesticides
WO2010088177A1 (en) * 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
US20130310362A1 (en) 2009-02-13 2013-11-21 Bayer Pharma Aktiegesellschaft Fused pyrimidines
US8957064B2 (en) 2009-02-13 2015-02-17 Bayer Intellectual Property Gmbh Fused pyrimidines
US8481503B2 (en) * 2009-03-06 2013-07-09 Merck Sharp & Dohme Corp. Combination cancer therapy with an AKT inhibitor and other anticancer agents
EP2406250B1 (en) 2009-03-11 2015-08-12 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010104705A1 (en) 2009-03-12 2010-09-16 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
EP2266985A1 (en) * 2009-06-26 2010-12-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Tricyclic Pyrimidine Derivatives as Wnt antagonists
EP2473495A1 (en) * 2009-09-18 2012-07-11 Almac Discovery Limited Pharmaceutical compounds
US20120252806A1 (en) * 2009-12-17 2012-10-04 Kelly Iii Michael J Inhibitors of akt activity
GB0922589D0 (en) * 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
CA2804845A1 (en) * 2010-07-12 2012-01-19 Stuart Ince Substituted imidazo[1,2-a]pyrimidines and -pyridines
EP2593447B1 (de) * 2010-07-15 2016-08-17 Bayer Intellectual Property GmbH 3-pyridyl-heteroarylcarboxamidverbindungen als schädlingsbekämpfungsmittel
MX336865B (es) 2011-04-07 2016-02-04 Bayer Pharma AG Imidazopiridazinas como inhibidores de quinasa akt.
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
EP2850200A1 (en) * 2012-05-17 2015-03-25 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
SMT201700595T1 (it) 2012-11-28 2018-03-08 Merck Sharp & Dohme Composizioni e metodi per trattare il cancro
US9156831B2 (en) 2013-01-23 2015-10-13 Astrazeneca Ab Chemical compounds
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
EP3091016A1 (en) 2015-05-05 2016-11-09 Technische Universität Dortmund Kinase inhibitors and their use in cancer therapy
CN107056755B (zh) * 2015-12-07 2019-02-22 苏州信诺维医药科技有限公司 五元杂环酰胺类wnt通路抑制剂
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
EP3678666B1 (en) 2017-09-07 2025-07-09 Augusta University Research Institute, Inc. Specific akt3 activator and uses thereof
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
EP4284804A1 (en) 2021-01-26 2023-12-06 Schrödinger, Inc. Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
IL312439A (en) * 2021-11-05 2024-06-01 Georgiamune Inc Akt3 modulators
WO2025196160A1 (en) 2024-03-20 2025-09-25 Specialty Operations France Cosmetic compositions, use thereof, and methods for using such compositions
WO2025196161A2 (en) 2024-03-20 2025-09-25 Specialty Operations France Cosmetic compositions, use thereof, and methods for using such compositions
WO2026136792A1 (en) * 2024-12-20 2026-06-25 Nuvalent, Inc. Heteroaryl compounds as modulators of akt activity

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831013A (en) * 1986-03-20 1989-05-16 Ciba-Geigy Corporation 2-substituted-e-fused-[1,2,4]triazolo[1,5-c]pyrimidines, pharmaceutical compositions, and uses thereof
MX9709897A (es) * 1995-06-06 1998-03-31 Pfizer 5-6-dihidro-9h-pirazol[3,4-c]-1,2,4-triazol[4,3-a]piridinas triciclicas y el uso de las mismas.
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
GB9824897D0 (en) * 1998-11-12 1999-01-06 Merck Sharp & Dohme Therapeutic compounds
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
JP4361276B2 (ja) 2001-04-10 2009-11-11 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害物質
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003086404A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Fused quinoxaline derivatives as inhibitors of akt activity
CA2480800C (en) * 2002-04-08 2008-09-23 Mark T. Bilodeau Inhibitors of akt activity
JP4451136B2 (ja) 2002-04-08 2010-04-14 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性阻害薬
WO2003086279A2 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
EP2573079A3 (en) * 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
AU2003284981B2 (en) 2002-10-30 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
DE602004026047D1 (de) 2003-04-24 2010-04-29 Merck Sharp & Dohme Hemmer der akt aktivität
US7414055B2 (en) 2003-04-24 2008-08-19 Merck & Co., Inc. Inhibitors of Akt activity
AU2004233828B2 (en) * 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
AU2004233827B2 (en) * 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
TWI344961B (en) 2003-10-15 2011-07-11 Ube Industries Novel indazole derivative
CN1942470A (zh) 2004-04-09 2007-04-04 默克公司 Akt活性抑制剂
US7544677B2 (en) * 2004-08-23 2009-06-09 Merck & Co., Inc. Inhibitors of Akt activity
JP2008521917A (ja) 2004-12-02 2008-06-26 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性のインヒビター
JP2008524339A (ja) 2004-12-15 2008-07-10 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性のインヒビター
AU2006216998B2 (en) * 2005-02-14 2010-12-23 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
JP2008535915A (ja) 2005-04-12 2008-09-04 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害剤
WO2006135627A2 (en) 2005-06-10 2006-12-21 Merck & Co., Inc. Inhibitors of akt activity
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt

Also Published As

Publication number Publication date
AU2006258124A1 (en) 2006-12-21
HRP20130429T1 (en) 2013-06-30
AU2006258124B2 (en) 2009-09-03
IL187690A0 (en) 2008-11-03
KR20080016627A (ko) 2008-02-21
TW200800166A (en) 2008-01-01
IL187690A (en) 2012-06-28
US8008317B2 (en) 2011-08-30
BRPI0611717A2 (pt) 2009-01-13
EP1898903A2 (en) 2008-03-19
EP1898903A4 (en) 2010-07-21
PL1898903T3 (pl) 2013-08-30
CR9580A (es) 2008-09-23
WO2006135627A3 (en) 2008-07-31
NZ563423A (en) 2010-05-28
JP2009501698A (ja) 2009-01-22
US20100222321A1 (en) 2010-09-02
CA2610888A1 (en) 2006-12-21
MX2007015578A (es) 2008-03-06
EP1898903B1 (en) 2013-03-27
ES2409168T3 (es) 2013-06-25
WO2006135627A2 (en) 2006-12-21
KR100959771B1 (ko) 2010-05-28
CA2610888C (en) 2011-02-08
RU2008100045A (ru) 2009-07-20
EP1898903B8 (en) 2013-05-15
PT1898903E (pt) 2013-06-28
RU2421454C2 (ru) 2011-06-20
NI200700320A (es) 2008-06-17
DK1898903T3 (da) 2013-07-01
JP5055494B2 (ja) 2012-10-24
AU2006258124B8 (en) 2010-01-07
NO20080150L (no) 2008-03-10

Similar Documents

Publication Publication Date Title
NI200700320A (es) Inhibidores de la actividad akt
ECSP099376A (es) Inhibidores de la actividad de la akt
WO2006091395A3 (en) Inhibitors of akt activity
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
EA200900227A1 (ru) Пептидомиметики smac, применимые в качестве ингибиторов iap (ингибитор белков апоптоза)
ECSP067080A (es) DIFENILIMIDAZOPIRIMIDINA Y AMINAS IMIDAZOL COMO INHIBIDORES DE ß-SECRETASA
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
CR20140544A (es) Compuestos para inhibir la progresión mitotica
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
MX2009003405A (es) Composiciones farmaceuticas de inhibidores de la histona desacetilasa y compuestos quelantes de metal, y complejos de quelato de metal-inhibidor de histona desacetilasa.
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
MX379353B (es) Compuesto de piperidina tipo quinoxalina sustituida y uso de los mismos.
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
WO2007059154A3 (en) Treatment of cancers with acquired resistance to kit inhibitors
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
AR111697A2 (es) Composición oftálmica para el tratamiento de las alergias oculares
ECSP078015A (es) 4-anilino-3-quinolinocarbonitrilos para el tratamiento de cáncer
WO2007008502A3 (en) Inhibitors of checkpoint kinases
WO2007084135A3 (en) Inhibitors of checkpoint kinases
DOP2009000132A (es) Inhibidores de la actividad de la akt
WO2006097472A3 (en) Novel inhibitors of glutathione-s-transferase